Since July 2023, three anti-amyloid medications have been FDA-approved for the treatment of Alzheimer’s disease, with more in development. These medications have the potential to improve the lives of those suffering from Alzheimer’s, but they also come with a serious side effect called amyloid-related imaging abnormalities (ARIA), which can cause swelling or small bleeding areas in the brain. People who carry the apolipoprotein E-E4 gene (APOE-e4) are at a higher risk of developing ARIA when taking anti-amyloid drugs. To help mitigate these risks, researchers have developed a new test called the EURORealTime APOE test that can determine which APOE variants a person may have, potentially predicting whether they would have a negative reaction to anti-amyloid medications.
In July 2023, the FDA approved lecanemab, the first anti-amyloid medication for the treatment of Alzheimer’s disease, under the brand name Leqembi. Since then, another medication, donanemab (Kisunla), has also received FDA approval, with more medications still in development. ARIA is a potential and serious side effect of anti-amyloid medications, where swelling or small bleeding areas of the brain occur. People with the APOE-e4 gene are at a higher risk of developing ARIA, which can limit the optimal dose of the medication and increase the chances of serious side effects. The EURORealTime APOE test can help identify individuals who are at risk for negative reactions to anti-amyloid drugs, allowing for personalized treatment plans to be developed.
The EURORealTime APOE test is a real-time PCR test that can amplify genomic DNA isolated from whole blood to detect the three APOE alleles that a person has in their genome. This test can determine whether a person has the APOE-e4 allele, which is the most important risk factor for Alzheimer’s disease. About 25% of people in the US have at least one APOE-e4 allele, and having two copies of this allele can increase the risk of developing Alzheimer’s disease by up to 15 times. Additionally, individuals with the APOE-e4 allele are more likely to experience the ARIA side effect when treated with anti-amyloid drugs for Alzheimer’s disease.
ARIA can take two forms: edema (ARIA-E) and hemorrhage (ARIA-H). ARIA-E involves brain swelling, which can lead to symptoms like headache or confusion, while ARIA-H occurs when small bleeding events in the brain occur. These side effects are associated with amyloid-targeting treatments and can be asymptomatic or result in serious and life-threatening events. Due to the potential risks of ARIA, it is recommended to screen patients for APOE genotypes before starting anti-amyloid drug treatments to discuss the potential risks. The EURORealTime APOE test can help identify individuals who may be at risk for developing ARIA and guide treatment decisions accordingly.
The EURORealTime APOE test is currently available for research use only, but further research and clinical studies are needed to better understand a person’s risk of developing ARIA when treated with anti-amyloid drugs for Alzheimer’s disease. Integrating this genotyping test into routine clinical practice and developing guidelines for its use in treatment planning would be beneficial. The test holds promise for accurately identifying patients at risk for severe side effects from anti-amyloid drugs, enabling more precise treatment planning and improving safety and efficacy of Alzheimer’s disease therapies. Larger, more diverse clinical trials are needed to further validate the test’s accuracy and reliability across different populations and ensure widespread adoption in clinical practice.
In conclusion, the EURORealTime APOE test provides a valuable tool for determining APOE genotypes and predicting potential negative reactions to anti-amyloid medications for Alzheimer’s disease. By identifying individuals at risk for ARIA, medical professionals can develop personalized treatment plans to minimize the risk of serious side effects and improve patient outcomes. Further research and clinical studies are needed to validate the test’s accuracy and reliability and integrate it into routine clinical practice to ensure widespread adoption and improve the safety and efficacy of Alzheimer’s disease therapies.
